The History of GLP-1 Medications: From Gila Monster to Weight Loss Revolution

In the early 1990s, endocrinologist Dr. John Eng was studying the venom of the Gila monster (Heloderma suspectum), a venomous lizard native to the American Southwest. In the venom, he discovered a hormone called exendin-4 that bore a striking resemblance to human GLP-1 — but with a crucial difference: it lasted much longer in the bloodstream.

Natural human GLP-1 is broken down by the enzyme DPP-4 within minutes. Exendin-4, shaped differently enough to resist this enzyme, could remain active for hours. This discovery opened the door to developing a medication that could mimic GLP-1's effects continuously rather than just for a few fleeting minutes after a meal.

Exenatide (brand name Byetta) became the first GLP-1 receptor agonist approved by the FDA in 2005, developed from that Gila monster compound. It was approved for type 2 diabetes and required twice-daily injections. While effective for blood sugar control, the frequent dosing was inconvenient.

Importantly, doctors began noticing something unexpected: patients were losing weight. In a field where most diabetes medications caused weight gain, this was remarkable. Patients also reported reduced appetite and — though the term wasn't widely used yet — less preoccupation with food.

Novo Nordisk developed liraglutide (Victoza for diabetes, 2010; Saxenda for weight management, 2014) — a modified human GLP-1 molecule that lasted long enough for once-daily injection. This was a significant improvement in convenience and patient compliance.

Saxenda became the first GLP-1 medication approved specifically for weight management, validating what doctors had observed: these drugs had powerful effects on appetite and weight beyond their diabetes benefits. But the weight loss was modest compared to what would come next.

Semaglutide represented a quantum leap. Also developed by Novo Nordisk, it was engineered to last long enough for once-weekly injection — a single shot every seven days. More importantly, it was dramatically more effective than its predecessors.

Ozempic was approved for type 2 diabetes in 2017. The STEP clinical trials for the higher-dose weight management version (Wegovy, approved 2021) showed average weight loss of roughly 15% of body weight — numbers previously seen only with bariatric surgery.

But the data told only part of the story. Patient communities began buzzing about something the clinical trials hadn't specifically measured: the dramatic reduction in food noise. Social media filled with astonished accounts — shared across patient communities— of people discovering what a quiet mind felt like for the first time. “Food noise” entered the mainstream vocabulary.

Eli Lilly took a different approach with tirzepatide, creating a molecule that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The theory: targeting two complementary hormone pathways would be more effective than one.

The results exceeded expectations. Mounjaro (approved for diabetes, 2022) and Zepbound (approved for weight management, 2023) showed average weight loss of approximately 21% at the highest doses — approaching what many patients achieve with gastric sleeve surgery.

For food noise reductionspecifically, tirzepatide patients often described the effect as even more dramatic than semaglutide. The “light switch” metaphor became common: one day the noise was there, the next it simply wasn't.

The impact of GLP-1 medications has extended far beyond medicine. They've sparked conversations about the biological basis of obesity, challenged decades of weight-related moral judgment, and forced society to reckon with the fact that “just eat less” was never adequate advice for millions of people whose brains were wired differently.

The concept of food noise— given a name and validated by these medications — has been particularly revelatory. People who thought everyone thought about food constantly discovered that wasn't true. People who blamed themselves for decades of diet failures learned it was biology, not character. The collective “oh” moment has been one of the most significant shifts in how society understands weight and appetite.

The GLP-1 field is moving at unprecedented speed. Oral semaglutide for weight management could eliminate injections. Triple agonists (GLP-1/GIP/glucagon) in clinical trials show even greater efficacy. Amycretin, a dual amylin/GLP-1 agonist, showed 13% weight loss in just 12 weeks in early trials. And long-acting formulations could reduce dosing to monthly or even less frequently.

Research into GLP-1 effects beyond weight — including cardiovascular protection, kidney disease, liver disease, Alzheimer's, and addiction — is expanding rapidly. The SELECT trial showed semaglutide reduced major cardiovascular events by 20%, leading to expanded FDA approvals. Some researchers believe GLP-1 receptor agonists may become the statins of the 2020s — widely prescribed for broad cardiometabolic protection.

What started with a curious scientist and a venomous lizard has become a revolution in how we understand and treat obesity, appetite, and the relentless phenomenon of food noise. And the story is still just beginning.